… mGluR5 pathway, aided mice modeling autism caused by the 16p11.2 mutation. Meanwhile that same GABA-boosting drug, … testing in clinical trials with fragile X patients. Phase 2 trials showed promise, but in 2017 a stage 3 trial narrowly …
… defined causes of autism, fragile X and chromosome 16p11.2 microdeletion, yielded promising results. He founded a … to run clinical trials in fragile X. The phase 2 and phase 3 studies yielded similarly poignant results: …
